Bafna Pharmaceuticals Ltd

BAFNAPH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹290 cr, stock is ranked 1,433
High RiskStock is 3.20x as volatile as Nifty
122.700.00 (+0.00%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹290 cr, stock is ranked 1,433
High RiskStock is 3.20x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
49.79
PB RatioPB Ratio
5.11
Dividend YieldDiv. Yield
Sector PESector PE
38.20
Sector PBSector PB
5.09
Sector Div YldSctr Div Yld
0.67%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202178.5045.0342.7371.97-16.73-18.87-24.735.83
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.34%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Rights Issue 
Announced OnNov 12, 2021

3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. The Board has constituted a Rights Issue Committee of Directors for the above purpose and has authorised the Committee to determine the terms of the Rights Issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement timing of the issue, appointment of intermediaries, etc., in consultation with the Lead Manager to the Right Issue and to decide all other matters relating to the Right Issue. Such details shall be informed and/or announced in due course as and when decided or required, as per applicable statutory provisions and depending upon the market conditions. The above proposal to issue of shares shall be subject to necessary approvals, confirmations and consents as may be necessary and in compliance with applicable law including the provisions of the Securities and Exchange Board of India (lssue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013 and the Rules made there under and as amended.The proposed Rights Issue will be a step towards meeting with the Minimum Public Shareholding requirements and is one of the prescribed methods in accordance with SEBI Circular No. CIR/CFD/CMD/14/2015 dated November 30, 2015, as amended. Accordingly, the Promoter may not participate in the proposed Rights Issue. | Download

3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. The Board has constituted a Rights Issue Committee of Directors for the above purpose and has authorised the Committee to determine the terms of the Rights Issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement timing of the issue, appointment of intermediaries, etc., in consultation with the Lead Manager to the Right Issue and to decide all other matters relating to the Right Issue. Such details shall be informed and/or announced in due course as and when decided or required, as per applicable statutory provisions and depending upon the market conditions. The above proposal to issue of shares shall be subject to necessary approvals, confirmations and consents as may be necessary and in compliance with applicable law including the provisions of the Securities and Exchange Board of India (lssue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013 and the Rules made there under and as amended.The proposed Rights Issue will be a step towards meeting with the Minimum Public Shareholding requirements and is one of the prescribed methods in accordance with SEBI Circular No. CIR/CFD/CMD/14/2015 dated November 30, 2015, as amended. Accordingly, the Promoter may not participate in the proposed Rights Issue. | Download

Financial Result Updates 
Announced OnNov 12, 2021

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2021. | Download

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2021. | Download

Cash Dividend 
Ex. DateSep 19, 2013

Final • Div/Share: ₹ 0.6

See all events